NSCLC Survival Benefit Seen With EGFR-TKI + Chemo

Median PFS benefit was just over 3 months in patients with EGFR-mutant NSCLC who had tumor suppressor gene co-mutations.
Medscape Medical News

source https://www.medscape.com/viewarticle/nsclc-survival-benefit-seen-egfr-tki-chemo-2025a1000nlj?src=rss